Oncolytics biotech

Oncolytics Biotech Inc (NASDAQ:ONCY)

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc.2019. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates.

© 2021 Cable News Network. A Warner Media Company. All Rights Reserved.
CNN Sans™ & © 2016 Cable News Network.

Sours: https://money.cnn.com/quote/forecast/forecast.html?symb=ONCY

Oncolytics Biotech, Inc. (USA)

About Oncolytics Biotech, Inc. (USA)

Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.


Biotechnology & Drugs

Executive Leadership

Wayne F. Pisano

Independent Chairman of the Board

Matthew C. Coffey

President, Chief Executive Officer, Director

Kirk J. Look

Chief Financial Officer

Andrew De Guttadauro

Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc.

Allison Hagerman

Vice President - Product Development

Key Stats

1.50 mean rating - 4 analysts

Revenue (MM, CAD)

Price To Earnings (TTM)


Price To Sales (TTM)


Price To Book (MRQ)


Price To Cash Flow (TTM)


Total Debt To Equity (MRQ)


LT Debt To Equity (MRQ)


Return on Investment (TTM)


Return on Equity (TTM)

Sours: https://www.reuters.com/companies/ONCY.O
  1. First print comics
  2. Rustic lamp
  3. De verdad spanish to english

Oncolytics Biotech, Inc.

Our Focus: Immunotherapy Combinations

Oncolytics is currently focused on immunotherapy combinations, including in our clinical studies with Bavencio®, Keytruda®, Opdivo®, Tecentriq®, and Retifanlimab.

Cancers grow in our bodies because our immune systems do not recognize these tumors as foreign or as a threat. They do this by applying the brakes to our immune systems – notably T cells – through receptors called checkpoints. Immunotherapies help our immune systems to recognize and kill cancer. Instead of attacking the tumor directly, immunotherapies leverage the power of a patient’s own immune system, enabling it to attack and kill cancer cells. One way in which immunotherapies do this is by working to prevent tumors from suppressing patient immune systems. For some patients, the suppressive effects of tumor immune suppression are profound. Using checkpoint inhibitors as an example, as few as 1-in-5 patients will respond to checkpoint blockade depending on the indication.  Responses could be limited by tumor microenvironments that do not have the key elements required for checkpoint blockade, which include:

  • The presence of T cells
  • An inflamed tumor
  • Expression of checkpoints

Pelareorep has demonstrated the ability to create a more permissive tumor microenvironment and conditions the tumor for multiple treatment combinations, including checkpoint inhibitors and potentially other immuno-oncology drugs, like CAR T therapies, bispecific antibodies, and CDK4/6 and PARP inhibitors. Pelareorep creates a new army of tumor-reactive T cells, causes these cells to infiltrate the tumor through an inflammatory process, and promotes the overexpression of checkpoints, including PD-1/PD-L1. By priming the immune system, we believe we can increase the percentage of patients who respond to immunotherapies and other cancer treatments to open up new indications where they have been limited to date. This vast opportunity is represented by our collaborations with leading oncology companies, including Merck, Bristol-Myers Squibb, Roche, Incyte, Adlai Nortye, and our Pfizer/Merck KGaA alliance in a variety of solid tumor and hematologic indications.

Sours: https://www.oncolyticsbiotech.com/

Oncolytics Biotech

Ambox current red Asia Australia.svg

This article needs to be updated. Please help update this article to reflect recent events or newly available information.(January 2014)


Traded as

TSX: ONC, Nasdaq: ONCY
Founded1998 Calgary, Alberta, Canada

Calgary, Alberta



Key people

Matt Coffey Ph.D. - President, and Chief Executive Officer, Chief Operating Officer; Kirk Look, CA - Chief Financial Officer; Andres A. Gutierrez, M.D., Ph.D. - Chief Medical Officer; Andrew de Guttadauro, President, Oncolytics Biotech (U.S.) Inc.
ProductsREOLYSIN, a first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies.

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.[1]


Oncolytics Biotech Inc. was founded in Calgary in 1998 in response to discoveries made on the oncolytic potential of reovirus made at the University of Calgary during the 1990s.[2][3] In June 2000, it began trading on the Toronto Stock Exchange (TSX). On October 5, 2001, it was listed on the NASDAQ.[4]

Since its inception, Oncolytics Biotech Inc. has worked to take REOLYSIN, its proprietary formulation of human reovirus, through the development and regulatory requirements necessary to develop it as a potential cancer therapeutic. In 2000, Oncolytics Biotech Inc. received permission to conduct its first phase I clinical trial, which was designed to test the safety of REOLYSIN in human patients. The positive results[5] of this first study led to the rapid and continuous expansion of Oncolytics’ clinical trial program, with phase 2 studies beginning in Canada in 2001, U.S. and subsequent cross-border studies beginning in 2002, and enrollment in a multi-site phase 3 trial beginning in 2010.[6] The company has conducted numerous clinical trials studying REOLYSIN in variety of cancers, including pancreatic, breast, head and neck, prostate, lung, colorectal, bladder and ovarian cancers.

The company was issued its first Canadian patent in August 2000, and currently holds more than 415 patents worldwide, including more than 60 U.S. and 20 Canadian patents, and more than 60 applications pending worldwide.


REOLYSIN is a first-in-class, systemically administered, immuno-oncolytic virus. REOLYSIN was developed from preclinical research done at the University of Calgary[2][3] by Jim Strong and Matt Coffey, Oncolytics' President, Chief Executive Officer and Chief Operating Officer.

REOLYSIN is a proprietary formulation of human reovirus, which is naturally found in mammalian respiratory and bowel systems.[7] Most people have been exposed to reovirus by adulthood, but the infection does not typically produce symptoms.[8] Reovirus was noted to be a potential cancer therapeutic when early studies suggested it reproduces well in certain cancer cell lines.[9][10] It has since been shown to replicate specifically in cells that have an activated Ras pathway with very little effect in cells that do not have active Ras pathways.[11] Activating mutations of the Ras protein and upstream elements of the Ras protein may play a role in more than two thirds of all human cancers, including most metastatic disease, which suggests that Reolysin may be an effective therapeutic for many Ras-activated tumor types and potentially for some cell proliferative disorders.[12][13][14]

In both single-arm and randomized phase 2 clinical studies, REOLYSIN, in combination with various chemotherapeutic agents, has shown a trend to improve overall survival (OS) in certain indications and patient populations, while having a limited impact on objective response rate (ORR) or progression-free survival (PFS), a therapeutic profile consistent with those observed with approved immunotherapies. Based on these observations, Oncolytics believes REOLYSIN has multiple components to its mechanism of action (MOA):[15]

  • Direct tumor lysis – selective viral replication in permissive cancer cells leading to tumor cell lysis;
  • Innate immune response – viral replication resulting in a cascade of chemokines/cytokines causing natural killer (NK) cells to recognize and attack cancer cells; and
  • Adaptive immune response – antigen presenting cells (APCs) display tumor-associated antigens (TAA) and viral-associated antigens (VAA) to educate T-cells to recognize and destroy cancer cells.

Research and Development Collaborations[edit]

Oncolytics Biotech Inc. has collaborated with the National Cancer Institute (NCI),[16] the University of Leeds,[17] the Canadian Cancer Trials Group (CCTG) (formerly the National Cancer Institute of Canada Clinical Trials Group)[18] and the Cancer Therapy & Research Centre at the University of Texas Health Science Center in San Antonio,[19] among others, to conduct multiple clinical trials in the United States and United Kingdom. Oncolytics is currently collaborating with Myeloma UK and Celgene Corporation,[20] the CCTG,[21] the NCI[22] and the University of Texas.[23] In May 2018, Oncolytics Biotech collaborated with Merck & Northwestern University for the research on second-line pancreatic cancer.[24]

Clinical Development[edit]

REOLYSIN has completed clinical trials in a variety of cancer types. The company's clinical development plan is based on drug combinations that can potentially boost each response of REOLYSIN's mechanism of action, with three development pathways: 1) chemo combinations (direct cell lysis) 2) immunotherapy combinations (adaptive immune response) and; 3) combination with (immunomodulators) IMiDs / targeted therapy (innate immune response).[25]

As part of REOLYSIN's registration pathway, Oncolytics, in partnership with CCTG, is conducting a phase 2 clinical trial in metastatic breast cancer patients receiving standard weekly paclitaxel therapy.[21] In March 2017, the company announced positive overall survival data from the open-label, randomized study where, in the intention-to-treat patient population, there was a statistically significant improvement in median overall survival from 10.4 months on the control arm to 17.4 months on the test arm.[26] In May 2017, Oncolytics announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for REOLYSIN for the treatment of metastatic breast cancer,[27] and in September 2017, the company announced a successful End-of-Phase 2 meeting with the FDA.[28]

Oncolytics is conducting its first study of REOLYSIN in combination with a checkpoint inhibitors in an open-label phase 1b trial. The trial will assess the safety and dose-limiting toxicity of REOLYSIN in combination with pembrolizumab (KEYTRUDA) and chemotherapy in patients with advanced or metastatic pancreatic adenocarcinoma who have failed, or did not tolerate, first line treatment.[29]

On March 16, 2017 Oncolytics announced that cancer charity Myeloma UK launched MUK eleven, a phase 1b trial studying REOLYSIN in combination with Celgene Corporation's immunomodulatory drugs (IMiDs), Imnovid (pomalidomide) or Revlimid (lenalidomide), as a rescue treatment in relapsing myeloma patients.[20] The first patient was treated in September 2017.[30]

Oncolytics is conducting two phase 2 clinical trials studying REOLYSIN in pancreatic cancer: in collaboration with the University of Texas, Oncolytics is studying REOLYSIN in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer,[23] and in collaboration with the NCI, Oncolytics is studying REOLYSIN in combination with carboplatin and paclitaxel as a first line treatment of patients with recurrent or metastatic pancreatic cancer.[22]


  1. ^"What is Reolysin? | Oncolytics Biotech Inc". Oncolytics Biotech Inc. Archived from the original on 2017-10-26. Retrieved 2017-10-25.
  2. ^ abStrong, JE; Tang, D; Lee, PW (1993). "Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency". Virology. 197 (1): 405–11. doi:10.1006/viro.1993.1602. PMID 8212574.
  3. ^ abCoffey, MC; Strong, JE; Forsyth, PA; Lee, PW (1998). "Reovirus therapy of tumors with activated Ras pathway". Science. 282 (5392): 1332–4. doi:10.1126/science.282.5392.1332. PMID 9812900.
  4. ^"Annual Report 12 April 2002". SEDAR. Canadian Securities Administrators. Retrieved 21 September 2019.
  5. ^Thirukkumaran, CM; Nodwell, MJ; Hirasawa, K; Shi, ZQ; Diaz, R; Luider, J; Johnston, RN; Forsyth, PA; et al. (2010). "Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic". Cancer Research. 70 (6): 2435–44. doi:10.1158/0008-5472.CAN-09-2408. PMID 20215509.
  6. ^"ONCOLYTICS BIOTECH INC. | Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers". Newswire.ca. 2011-06-20. Retrieved 2011-08-08.
  7. ^Nirbert, M. L.; Schiff, L. A.; Fields, B. N. (1996). "Reoviruses and their Replication". In Fields, Bernard N.; Knipe, David Mahan; Howley, Peter M. (eds.). Fundamental Virology (3rd ed.). Philadelphia: Lippincott-Raven. ISBN .[page needed]
  8. ^White, CL; Twigger, KR; Vidal, L; De Bono, JS; Coffey, M; Heinemann, L; Morgan, R; Merrick, A; et al. (2008). "Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial". Gene Therapy. 15 (12): 911–20. doi:10.1038/gt.2008.21. PMID 18323793.
  9. ^Hashiro, G; Loh, PC; Yau, JT (1977). "The preferential cytotoxicity of reovirus for certain transformed cell lines". Archives of Virology. 54 (4): 307–15. doi:10.1007/BF01314776. PMID 562142.
  10. ^Duncan, MR; Stanish, SM; Cox, DC (1978). "Differential sensitivity of normal and transformed human cells to reovirus infection". Journal of Virology. 28 (2): 444–9. PMC 354293. PMID 214572.
  11. ^Strong, JE; Coffey, MC; Tang, D; Sabinin, P; Lee, PW (1998). "The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus". The EMBO Journal. 17 (12): 3351–62. doi:10.1093/emboj/17.12.3351. PMC 1170673. PMID 9628872.
  12. ^Duursma, AM; Agami, R (2003). "Ras interference as cancer therapy". Seminars in Cancer Biology. 13 (4): 267–73. doi:10.1016/S1044-579X(03)00040-3. PMID 14563121.
  13. ^Bos, JL (1989). "Ras oncogenes in human cancer: a review". Cancer Research. 49 (17): 4682–9. PMID 2547513.
  14. ^Norman, KL; Lee, PW (2005). "Not all viruses are bad guys: the case for reovirus in cancer therapy". Drug Discovery Today. 10 (12): 847–55. doi:10.1016/S1359-6446(05)03483-5. PMID 15970267.
  15. ^"Oncolytics Biotech Inc. Announces Registration Pathway and Clinical Development Plan – Oncolytics Biotech Inc". Oncolytics Biotech Inc. Retrieved 2017-10-25.
  16. ^"ONCOLYTICS BIOTECH INC. | Oncolytics Biotech(R) Inc. Announces Randomized Phase II Ovarian Cancer Study to be Conducted by the Gynecologic Oncology Group and Sponsored by the National Cancer Institute". Newswire.ca. 2011-06-20. Retrieved 2011-08-08.
  17. ^"Bulletin Board". Therapy. 6 (2): 191–197. 2009. doi:10.2217/14750708.6.2.191.
  18. ^"Oncolytics Biotech Inc. Announces Completion of Enrollment in Randomized Phase II Colorectal Cancer Study – Oncolytics Biotech Inc". Oncolytics Biotech Inc. Retrieved 2017-10-25.
  19. ^"ONCOLYTICS BIOTECH INC. | Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration". Newswire.ca. 2011-06-20. Retrieved 2011-08-08.
  20. ^ ab"Oncolytics Biotech Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN in Combination with Imnovid or Revlimid in Patients with Myeloma – Oncolytics Biotech Inc". Oncolytics Biotech Inc. Retrieved 2017-10-25.
  21. ^ ab"A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov". Retrieved 2017-10-25.
  22. ^ ab"Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer - Full Text View - ClinicalTrials.gov". Retrieved 2017-10-25.
  23. ^ ab"A Study of REOLYSIN in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma - Full Text View - ClinicalTrials.gov". Retrieved 2017-10-25.
  24. ^"Oncolytics collaborates with Merck & Northwestern University to begin phase 2 study of Reolysin in combo with Keytruda to treat second line pancreatic cancer". www.pharmabiz.com. Retrieved 2018-05-31.
  25. ^"Clinical Trials | Reolysin | Oncolytics Biotech Inc". Oncolytics Biotech Inc. Archived from the original on 2017-10-26. Retrieved 2017-10-25.
  26. ^"Oncolytics Biotech Inc.'s REOLYSIN Provides Statistically Significant Improvement in Overall Survival in Canadian Cancer Trials Group Sponsored Randomized Phase 2 Study in Metastatic Breast Cancer – Oncolytics Biotech Inc". Oncolytics Biotech Inc. Retrieved 2017-10-25.
  27. ^"Oncolytics Biotech Inc. Announces FDA Fast Track Designation for REOLYSIN in Metastatic Breast Cancer – Oncolytics Biotech Inc". Oncolytics Biotech Inc. Retrieved 2017-10-25.
  28. ^"Oncolytics Biotech Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN in Metastatic Breast Cancer – Oncolytics Biotech Inc". Oncolytics Biotech Inc. Retrieved 2017-10-25.
  29. ^"Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma - Full Text View - ClinicalTrials.gov". Retrieved 2017-10-25.
  30. ^"Oncolytics Biotech Announces First Patient Treated in MUK eleven Study – Oncolytics Biotech Inc". Oncolytics Biotech Inc. Retrieved 2017-10-25.

External links[edit]

  • oncolyticsbiotech.com
  • RSS feed subscriptions to company press releases and presentations can be set up from the company webpage at [1])
  • Detailed notes explaining how an Oncolytics shareholder who is a US taxpayer can navigate the company's US tax status as a so-called "Passive foreign investment company" (PFIC).
Sours: https://en.wikipedia.org/wiki/Oncolytics_Biotech

Biotech oncolytics

I was a little upset, but quickly ran into the shower, pulled on one of my thongs and went out into the yard. A few minutes later Andrei's car drove up, he honked and I got into the car, in the front seat. What, the bitch tensed. Let's change back, let's get to know each other.

Sveta was beautiful: a light blouse, a butterfly around her neck, black mesh tights. On her slender legs, a short black skirt and loose brown hair. We were ready.

You will also like:

There were nine more procedures ahead, and even they themselves are more than good. Even a few hours after the procedure, the inside was pleasantly drawn, causing excitement and awakening vivid fantasies. Whatever you say, but the hand of the master is felt, it is felt very well.

7405 7406 7407 7408 7409